MYELODYSPLASTIC SYNDROME; MDS

specific

Comment: may be designated as having features of a named human MDS; Morphologic dysgranulopoiesis, dyserythropoiesis, and/or dysplastic megakaryocytes (with or without increased immature forms/blasts)

46

Centers

24

Active Trials

Cancer Funding

Top Centers for MYELODYSPLASTIC SYNDROME; MDS(46)

Ranked by research excellence score (trials · grants · publications). Methodology →

#CenterScore
1
NCI Comprehensive
High-Volume Research Center
73.1
2
NCI Comprehensive
High-Volume Research Center
70.7
3
High-Volume Research Center
70.7
4
High-Volume Research Center
70.7
5
High-Volume Research Center
70.7
6
NCI Comprehensive
Active Research Program
62.3
7
NCI Comprehensive
Active Research Program
62.3
8
NCI Comprehensive
Active Research Program
62.3
9
NCI Comprehensive
Active Research Program
62.3
10
NCI Comprehensive
Active Research Program
62.3
11
NCI Comprehensive
Active Research Program
62.3
12
NCI Comprehensive
Active Research Program
62.3
13
NCI Comprehensive
Active Research Program
62.3
14
NCI Clinical
Active Research Program
62.3
15
Active Research Program
62.3
16
Active Research Program
62.3
17
BC CancerVancouver, BC
Active Research Program
62.3
18
Active Research Program
62.3
1942.3
2042.3
21
NCI Comprehensive
42.3
22
NCI Comprehensive
42.3
23
NCI Comprehensive
42.3
24
NCI Comprehensive
42.3
25
NCI Comprehensive
42.3
2642.3
2742.3
28
NCI Comprehensive
42.3
2942.3
30
Masonic Cancer CenterMinneapolis, MN
NCI Comprehensive
42.3
31
NCI Comprehensive
42.3
32
NCI Comprehensive
42.3
33
NCI Clinical
42.3
34
NCI Comprehensive
42.3
3542.3
36
Cedars-Sinai CancerLos Angeles, CA
42.3
3742.3
3842.3
39
NCI Comprehensive
42.3
40
Rutgers Cancer InstituteNew Brunswick, NJ
NCI Comprehensive
42.3
41
NCI Comprehensive
42.3
4242.3
4342.3
4442.3
4542.3
4642.3

Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →